Satellos Bioscience Inc. Insider Trading

Satellos Bioscience Inc. is a clinical-stage drug development company operating in Canada, the United States, and Australia. The company focuses on restoring natural muscle repair and regeneration in people with degenerative muscle diseases. To support its research, Satellos uses a proprietary discovery platform called MyoReGenX, which is an automated microscopy system designed to replicate the muscle stem cell environment outside the body. The company is developing SAT-3247, an oral small molecule drug candidate intended for the treatment of Duchenne muscular dystrophy. Satellos holds a license agreement with the Ottawa Hospital Research Institute and an option agreement with the University of British Columbia. The company operates within the biotechnology industry and the broader healthcare sector. Founded in 2018 and headquartered in Toronto, Canada, Satellos works to advance scientific understanding of muscle regeneration and translate that knowledge into potential treatments for patients affected by serious muscle diseases.